Manufacturing and Use of Valve Leaflet Implants
ECM-based valve leaflet implants address the limitations of current materials by providing a biocompatible, durable, and growing solution for congenital heart diseases, reducing immune responses and complications.
Patent Information
- Application Number
- JP2024537927
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-23
- Filing Date
- 2022-12-21
- Publication Date
- 2024-11-29
AI Technical Summary
Current heart valve repair materials, such as chemically treated animal pericardium and synthetic membranes, induce chronic inflammatory responses and are unsuitable for pediatric use due to complications like pulmonic valve leakage and thromboembolic issues, limiting their effectiveness in treating congenital heart diseases like Tetralogy of Fallot.
Development of fully biological valve leaflet implants composed of extracellular matrix (ECM) secreted by human dermal fibroblasts, which are biocompatible and mechanically robust, allowing for tissue integration and growth, eliminating the need for chemical fixation and reducing immune responses.
The ECM-based implants provide a durable and biocompatible solution that minimizes immune reactions, supports tissue regeneration, and adapts to the growing child, offering superior durability and reduced complications compared to traditional materials.
Smart Images

Figure 2024544419000001 
Figure 2024544419000002 
Figure 2024544419000003
Abstract
Description
[Technical field]
[0001] The present invention relates to the manufacture of valve leaflet implants and their use in the treatment of congenital heart disease, cardiac, venous and lymphatic valvular diseases, in particular tetralogy of Fallot.
[0002] In the following description, references between brackets [] refer to the list of references presented at the end of this document. [Background technology]
[0003] Congenital heart disease is a malformation of the heart that is present at birth. Its severity can vary from very minor forms that never cause cardiac dysfunction to very severe forms that require treatment. Congenital heart disease occurs when the chambers, walls or valve cusps of the heart - or blood vessels near the heart - do not develop normally before birth. Most congenital heart diseases can be classified into two broad categories: cyanogenic and non-cyanogenic (the term cyanogenic comes from the bluish color of the skin of affected patients). The severity of the damage varies from case to case.
[0004] Noncyanogenic congenital heart diseases can result from various malformations: holes or septal defects in the heart (atrial septal defect (ASD), ventricular septal defect (VSD)) and blockages in blood flow (stenosis, atresia, absence). In some cases, medications may be sufficient to treat the patient, but in many cases, the defective heart valve needs to be repaired. Since the availability of human heart valves is very limited (sourced from cadavers) or does not exist in children for size reasons, repairs generally involve the use of biological materials, in particular valves made from animal pericardium (especially bovine) and usually chemically treated (e.g. glutaraldehyde fixed) to avoid rejection and rapid degradation. This strategy underpins the design of all so-called biological valves currently on the market, since they are of animal origin and are attached to a synthetic support structure, often including a type of stent
[20] . However, this fixation causes a chronic nonspecific inflammatory response known as the "foreign body reaction" (FBR), similar to the one observed when synthetic biomaterials are implanted, which is the main cause of transplant complications. However, FBR is much weaker than the specific rejection directed towards intact animal tissues, hence the advantage of fixation. Moreover, by denaturing proteins, the bond makes them insensitive to host enzymes that can usually degrade them quickly. The use of human tissues obtained from the patient's pericardium and thus not requiring chemical fixation is a possibility that has been investigated
[21] . This seems very promising, but the availability, the quality variability and the quality itself, the fragility, the additional operation time, as well as the outcome of the implantation at the donor site are all variables that can complicate this approach. All these complications are eliminated by using tissue engineered biomembranes as proposed in this invention.
[0005] The use of "bioengineered films", supposed to be obtained from biodegradable polymeric materials or from proteins purified and then reconstituted as a matrix, has also been evoked in the case of
[20] . Firstly, the use of the term "film" suggests to the skilled artisan a very thin covering (Le Petit Robert dictionary: "Very thin layer (of a material)"). A literature review in PubMed confirms that the use of this term generally refers to a very small layer of material. Such films do not seem to be appropriate, since they are much thinner compared to sheets of tissue in order to provide sufficient puncture resistance. Furthermore, this type of material is used in an approach based on a delicate balance between the phenomena of material degradation and the generation of new tissue. This balance is very difficult to control, given that these phenomena vary greatly from individual to individual. But more important is the fact that the skilled artisan understands "bioengineered" to mean either structures made from chemically treated animal (or cadaveric) tissues, or structures made from proteins solubilized / purified from animal / human tissue extracellular matrix and then reconstituted by various physical / chemical processes. This realization is confirmed by reading patent application US20030229394A1
[22] , in which the authors divide matrices made from extracellular matrix proteins (mainly collagen) into 1) native tissue or 2) "synthetic" collagen-based matrices, where "synthetic" does not mean "made from polymers" as is often the case, but rather "made from proteins extracted from native tissues", as stated in paragraph 79, where "synthetic tissue matrices" are described.
[0006] Tetralogy of Fallot is one of the most common forms of cyanogenic congenital heart disease. It accounts for 7-10% of newborns with congenital heart disease [1, 2] and combines pulmonary valve stenosis, right ventricular hypertrophy, ventricular septal defect (VSD), and overriding aortic stenosis. These abnormalities affect the structure and ability of the beating heart, leading to stenosis of the right ventricular outflow tract (RVOT) and ultimately to oxygen desaturation in arterial blood. Surgical repair involves closing the VSD and removing the RVOT stenosis at approximately 6 months of age. In over 70% of cases, RVOT stenosis is corrected by placement of a transannular patch, which unfortunately results in pulmonary valve leakage [3, 4]. If left untreated, this pulmonary valve leakage leads to right ventricular dilation and dysfunction, which is associated with an increased risk of ventricular arrhythmias and sudden death in adulthood. The use of stented biological or industry-supplied mechanical valves in this infant population remains completely impossible [5]. To limit pulmonary valve leakage, techniques such as the use of a monocuspid valve have been developed [6]. This valve can be made from biological materials, in particular by using bovine pericardium [5] or synthetic polytetrafluoroethylene (PTFE) membranes [6] that have been chemically treated to prevent rejection. However, these materials have limitations. Glutaraldehyde-treated bovine pericardium and synthetic membranes are relatively flexible, very strong, and easy to handle, but are associated with thromboembolic complications and / or infective endocarditis [7-9]. Moreover, these materials are recognized as foreign bodies that cause a chronic inflammatory response. Polytetrafluoroethylene (PTFE) membranes, like all synthetic materials, are also a source of serious infections. Finally, current options show ineffective short- and mid-term results in limiting pulmonary valve leakage.
[0007] Thus, there is a real clinical need to develop new materials for repairing valves, such as heart valves, without the adverse effects described.
[0008] We propose to use a completely biological biomaterial composed of the extracellular matrix (ECM) secreted by human dermal fibroblasts, which is truly biocompatible [10-13]. Its remarkable biological compatibility comes from the structure of the ECM, which presents different advantages in addition to those of the biological or human nature of the proteins of which it is composed. During implantation, the body's immune system is able to recognize the foreign origin of the proteins thanks to its "adaptive" immune system, but also abnormal (or "denatured") ECM structures thanks to its "innate" immune system. As a consequence, if the ECM is damaged by physical, thermal or infectious trauma, the body can rapidly digest the damaged ECM using macrophage-type cells to allow specialized fibroblast-type cells to reconstruct the ECM. This is the mechanism at work when a collagen matrix produced by physical / chemical methods is implanted in the living body. Since it does not have a "physiological" structure, but rather a denatured one, it is rapidly degraded by the innate immune system [23-25]. The fact that the ECM is produced by cultured cells in the laboratory and is not subsequently chemically processed means that the structure of the ECM is close enough to the physiological structure to allow it to be "accepted" by the host, or, in other words, not to provoke an innate immune response that would destroy it. It is this structural feature that distinguishes it from all other matrices produced by physical / chemical methods from proteins extracted from tissues (human or animal). Moreover, this ECM, produced in sheet form on the surface of a culture flask, is easy to handle and mechanically robust after 6-8 weeks of culture [13, 14]. This robustness, achieved without chemical treatment (e.g., cross-linking), is also due to the ECM formed by cultured cells that produce a matrix of densely organized collagen fibrils combined with a large number of other matrix proteins [26-27]. Finally, it should be noted that the structure of this ECM produced by cells in the laboratory is also different from that of ECM obtained from tissues taken directly from mammals.This is because in situ harvested tissues contain numerous structures (hairs, nerves, blood and lymphatic vessels, glands, membranes, limiters, etc.) that are not present in the in vitro produced ECM sheets. Furthermore, these harvested tissues contain numerous cell types, whereas in vitro produced ECM sheets contain only a single cell type (typically fibroblasts). As a result, the valve leaflets produced in vitro are much more homogeneous in terms of structure and composition than the harvested tissues in vivo. This may have both mechanical and biological advantages. Furthermore, the valve leaflets offer greater reproducibility due to their in vitro preparation mode, which may be advantageous in terms of quality control in a commercial production situation. As a result, the structure of this material is very specific and distinguishes it from other materials used to manufacture valve leaflets.
[0009] This biomaterial has already been used in vascular applications in humans [15-18]. In this context, sheets of ECM were rolled up and fused to form blood vessels, which were then transplanted into patients suffering from end-stage renal failure [17, 18]. The transplantation results showed a high rate of transluminal patency (up to 3 years) [17, 18]. Furthermore, this study demonstrated that ECM sheets constructed without synthetic components can indeed integrate with native tissues, be remodeled by host cells, and be resistant to infection. Its biological structure, human origin, and the absence of chemical treatments (e.g. glutaraldehyde fixation) allow this biomaterial to be accepted by patients without the risk of rejection, rapid degradation or chronic inflammation, unlike ECMs derived from animal tissues, which are always chemically treated to mask their xenogeneic origin and slow down the degradative action of host enzymes secreted to destroy the denatured matrix. Furthermore, data show that biomaterials produced by allogeneic fibroblasts (derived from a donor different from the recipient) do not induce specific adaptive immune responses
[15] . Furthermore, a new generation of biological threads has been produced by cutting sheets of ECM into multiple ribbons. These ribbons can be twisted to form denser threads with different mechanical properties than ribbons
[14] . Recent studies have demonstrated the feasibility of using these ECM threads or ribbons as sutures for skin wound closure
[14] .
[0010] This biomaterial, with a puncture resistance of up to 2-6 kgf
[26] , has also been used to construct valve implants, which include a tubular structure and at least two ECM sheets (cusps or leaflets) connected to said structure. The sheets are as defined above (see "Single-layered tissue sheet" from International Application WO 20123 / 142879)
[19] . This biological implant has never been proposed for valve leaflet repair in children with congenital heart disease, in particular tetralogy of Fallot. Summary of the Invention
[0011] The present invention addresses precisely this need by proposing a biological implant comprising or consisting of a sheet of tissue (hereinafter also called ECM sheet) composed of the extracellular matrix (ECM) secreted by cells, preferably human cells, in culture and possibly the cells themselves, in combination with synthetic and / or modified biological threads or ribbons derived from the same biological material, which is used to create a pocket-type leaflet implant into which biological samples and / or active ingredients can be inserted before implantation in order to optimize tissue regeneration.
[0012] To this end, we developed a method for the production of a fully biological valve leaflet implant (Figure 1) from the ECM sheets defined above, from which we cut pieces that were folded once on themselves to form pocket-shaped valve leaflets. In parallel, the ECM sheets were also cut into ribbons to produce biological ECM threads. Once the pieces and ECM threads or ribbons were obtained, the leaflets or cusps of the native pulmonary valve, optionally containing living cells, were extracted, micronized and placed within the pocket-shaped leaflets. The pocket was then closed and the construct was sutured at the pulmonary outflow tract using biological or synthetic sutures or tapes. The space between the two sheet layers formed by the pocket closure was not sealed / fused to allow it to be filled with cells, tissue fragments or active ingredients. This innovative combination allowed the production of a fully biological valve leaflet implant that can be easily accepted by the host, can be colonized by host cells, can be remodeled after implantation (e.g. by a growing child treated for tetralogy of Fallot), and can be altered within the patient. In other words, the leaflet implant has the potential to grow, unlike prior art implants (e.g., having stents, fixed animal pericardium, polymeric films, or bioengineered films made from isolated and reconstituted proteins) that require removal and replacement by open heart surgery with associated high mortality rates. Thus, the leaflet implant according to the present invention has potential for pediatric use.
[0013] The human nature and quasi-natural structure of this ECM removes the need for fixation to prevent its degradation or to reinforce it, allowing the leaflet implant according to the invention to be accepted by the recipient patient without rejection or chronic inflammation with visible neovascularization in 2 weeks. This promises a better efficacy and durability than valves or leaflets made from materials of animal or synthetic origin. Using reconstituted ECM requires chemical treatments that either result in complete degradation and failure of the device within a few weeks or make it the source of chronic inflammation that is the cause of complications and failure of the leaflet device.
[0014] Fabrication of sheets of extracellular matrix (ECM) secreted by cells Cells are seeded onto the substrate with culture medium and generate ECM sheets after a long culture period. The ECM sheets are optionally processed for storage. The ECM sheets may or may not be separated from the substrate using a fixation device. This device prevents tissue shrinkage during culture and processing for storage. Finally, the ECM sheets are cut into piece ECM sheets.
[0015] The cells may be of human origin. The cells may be autologous or allogeneic. The cell type may be, for example, mesenchymal stem cells, induced pluripotent stem cells, primary adult mesenchymal cells (such as dermal fibroblasts), immortalized cells, or a mixture thereof.
[0016] Seeding concentration depends on the cell type and can range from 1000 cells / cm to 100,000 cells / cm.
[0017] The substrate can be selected from standard plastic culture flasks, thermosensitive culture flasks, different or similar ECMs (e.g., autologous human, allogeneic human, xenogeneic ECM, etc.), processed biological membranes (e.g., chemically treated pericardium, amniotic membrane of various origins, etc.), synthetic membranes (e.g., polytetrafluoroethylene, Dacron, silicone, etc.), hydrogels (e.g., collagen, alginate, fibrin, etc.), hybrids of the above substrates. The substrate can be coated with adhesive proteins (e.g., RGD peptide, fibrin, etc.) or gelatin to promote cell attachment. The substrate can have different shapes (e.g., customized, circular, rectangular, square, triangular, octagonal, pentagonal, etc.) to obtain the desired ECM sheet format.
[0018] The culture medium contains, but is not limited to, ascorbic acid compounds and serum for ECM production and assembly. Its composition depends on the cell type and is typically changed three times a week. The culture period varies from 4 to 24 weeks, preferably from 16 to 20 weeks, and more preferably from 6 to 8 weeks.
[0019] For storage, the ECM can be untreated, dehydrated, devitalized (a method consisting of freezing an ECM sheet at -80°C, thawing it at room temperature, dehydrating it overnight at room temperature, preferably under sterile flow in a fume hood, and finally rehydrating it at room temperature before use), decellularized, treated with glutaraldehyde solution, or a combination thereof. The decellularized ECM can be recellularized with the cells mentioned above, or endothelialized using autologous or allogeneic cells (e.g., umbilical vein endothelial cells (HUVEC), adipose tissue-derived stromal vascular fraction (SVF) cells, microvascular cells, etc.). Depending on the treatment, the ECM can be stored at -80°C, -20°C, 4°C, or room temperature. The fixation device can be a sterile stainless steel holder, a sterile plastic holder, a sterile paper holder, depending on the culture flask.
[0020] This ECM sheet is not a native tissue, nor is it a synthetic tissue generated from proteins extracted from native tissue and reconstituted into tissue derived from tissue bioengineering. This ECM sheet is assembled by cells in culture. The result is a non-fixed sheet of human ECM with a physiological structure. For these reasons, the ECM sheet has significant mechanical strength, does not provoke an immune / inflammatory response, and can interact normally with recipient cells to allow for a slow remodeling rather than a degradation process.
[0021] Manufacturing yarn or ribbon from ECM The ECM sheet is cut into ribbons that may be twisted (e.g., 0-10 turns / cm) to form wires. The ECM sheet may be cut using a machine with spaced circular blades, a laser system, an ultrasonic system, an electric arc system, a scalpel blade, or scissors. The ribbons may be 0.1-10 mm wide, with the length depending on the substrate used. The ribbons may be formed directly on the culture flask in the desired format. The ribbons may be twisted to modify their properties. At least two ribbons may be joined together using twisting methods, biological adhesives, culture ECM deposition, or combinations thereof to improve their mechanical properties. The thread or ribbon may then be attached to a surgical needle (e.g., tied to an eye; the eye may be crimped to secure the thread or ribbon to the needle).
[0022] For storage, the threads or ribbons can be untreated, dehydrated, devitalized, decellularized, glutaraldehyde-treated, or combinations thereof. Decellularized threads or ribbons can be recellularized with cells as described above, or endothelialized using autologous or allogeneic cells (e.g., HUVECs, cells from the vascular stromal fraction of blood, microvascular cells, etc.). Depending on the treatment, the threads or ribbons can be stored at -80°C, -20°C, 4°C, or room temperature.
[0023] These threads or ribbons are less likely to cause an inflammatory response and can be reformed, unlike traditional sutures, which are generally made from permanent plastics (e.g., polypropylene), helping to avoid complications and allowing them to grow with the child.
[0024] Particle creation and insertion Particles containing living cells can be micronized and placed inside the pocket leaflet implant.
[0025] For example, the particles can be derived from: native pulmonary valve leaflets, native dermis (autologous, allogeneic or xenogeneic), tissue engineered ECM, any tissue engineered matrix, cell suspensions (primary cells, , mesenchymal stem cells, induced pluripotent stem cells (iPSCs), etc.), cell aggregates (e.g., spheroids, organoids), extracellular vesicles or active ingredients (e.g., drugs), or combinations thereof.
[0026] The particles can be obtained using a machine with spaced circular blades, a laser system, an ultrasonic system, an electric arc system, a scalpel blade, scissors, or a grinder.
[0027] The particles can be placed into the bag using a spoon (surgical instrument), a pipette, or a syringe.
[0028] Thus, according to one aspect, the present invention relates to a pocket-type leaflet implant, comprising: The invention includes a piece of tissue sheet comprising cells in culture, preferably a human-secreted extracellular matrix, and optionally the cells folded once upon themselves to form a pocket region, wherein all or a portion of the opposing edges of the folded piece are joined to one another.
[0029] For purposes of the present invention, "cusp" means that portion of a valve consisting of a sheet of tissue that moves with a fluid (preferably blood) to allow the fluid to flow in one direction and prevent the fluid from flowing in the other direction. A valve may have one, but more commonly there are two or three or even more cusps.
[0030] For purposes of the present invention, a "pocket-type leaflet" is a leaflet that includes a hollow structure for holding one or more objects (e.g., cells, tissue particles, biomaterial particles, etc.) that may be placed therein.
[0031] For the purposes of the present invention, a "tissue sheet consisting of extracellular matrix secreted by cells (preferably human) in culture" means a deposit of insoluble proteins that accumulates on the inner surface of the bottom wall of a container in which the cells are cultured under conditions that favor said deposit. More specifically, when this deposit is separated from the surface, it is a tissue sheet.
[0032] For purposes of the present invention, "pocket area" means an empty space (hollow structure) created by folding a piece of ECM sheet and closing all or part of the opposing edges of said piece.
[0033] For purposes of this invention, "opposing edges" are defined as edges of an ECM sheet piece where adjacent flat portions are essentially parallel and lean against one another in such a way that they may be joined.
[0034] According to certain embodiments of the invention, all or part of the opposing edges of the folded piece are joined together by sutures using threads or ribbons derived from biologically modified (silk, chitosan, collagen, animal intestinal wall, etc.), synthetic and / or tissue sheets as defined herein.
[0035] For the purposes of the present invention, "(synthetic) thread or ribbon" means a thread or ribbon made from chemically synthesized materials used for the preparation of surgical or medical devices.
[0036] According to certain embodiments of the invention, the implant comprises a biological sample and / or an active ingredient within the pocket area.
[0037] A "biological sample" in the sense of the present invention is preferably a part of the patient's dysfunctional valve leaflet that is taken and cut into small pieces using common surgical tools (e.g. scissors) in the operating room. The size of the pieces may vary. These pieces are biological samples that are placed in the valve pocket area to provide a cell population that will repopulate the tissue. Other tissues (e.g. dermis, connective tissue, bone marrow, blood vessels, blood, adipose tissue, etc.) can be used. Other cell sources are envisaged (e.g. cells from the same patient but that can be cultured in vitro and subjected to different treatments (e.g. differentiation or dedifferentiation). These cells can be from different parts of the body. They can be assembled into larger or smaller clusters (organoids). Several cell types can be combined. The cells can also be combined with one or more biomaterials (biological or synthetic) to enhance their survival or function, following a wide range of delivery strategies. The cells can also be derived from another individual (allogeneic) or species (xenogeneic). The above options can be combined.
[0038] For the purposes of this invention, "active ingredient" means a pharmacological (non-biological) agent that has a positive effect on leaflet function, for example, by promoting the migration or proliferation of the patient's own cells to achieve more rapid or more effective tissue recolonization. Pharmacological agents may also have anti-thrombotic effects.
[0039] According to certain embodiments of the invention, the biological sample is derived from at least one leaflet of the subject's valve.
[0040] A "valve" within the meaning of the present invention is a tubular structure having within its lumen one or more leaflets that allow fluid to flow in one direction but not the other.
[0041] According to another aspect, the present invention relates to a method for manufacturing a valve leaflet implant according to the present invention, said method comprising the steps of: a) culturing a sheet of tissue as defined above; b) cutting pieces of said sheet of tissue obtained in step a); c) folding the piece from step b) once upon itself to form a pocket area; and d) joining all or a portion of the opposing edges of the folded piece from step c).
[0042] According to a particular embodiment of the method of the invention, the joining of step d) is achieved by suturing with threads or ribbons that are biologically modified, synthetic and / or derived from tissue sheets as defined in the present invention.
[0043] According to a particular embodiment of the method of the invention, said method further comprises a step d') of filling the pocket area with a biological sample and / or an active ingredient prior to the complete joining of step d).
[0044] According to certain embodiments of the method of the present invention, the biological tissue sample is derived from at least one leaflet of the subject's valve.
[0045] According to yet another aspect of the invention, the leaflet implant according to the invention is for use as a medicament.
[0046] According to yet another aspect of the invention, the leaflet implant according to the invention is for use in the treatment of a condition selected from congenital heart disease, cardiac, venous and lymphatic valvular disease.
[0047] According to a particular embodiment of the invention, the congenital heart disease is Tetralogy of Fallot.
[0048] Other advantages over those disclosed in the present application may also be apparent to those skilled in the art upon reading the following examples, which are given by way of illustration. [Brief description of the drawings]
[0049] [Figure 1] 1 illustrates a method of manufacturing a valve leaflet implant according to the present invention. [Diagram 2] Shown is the pattern used to cut a 2.4 m long, 5 mm wide biological ribbon. [Diagram 3] Figure 1 shows the steps involved in the crimping of biological sutures. A hydrated biological ribbon is twisted at one end over a length of approximately 2 cm at 5 turns / cm to form a thread. During this stage, the twisted area is gently massaged until completely dry to distribute the twist and obtain a dry thread with a uniform diameter. This homogenous zone is then inserted into the eye of a surgical needle to be crimped. [Figure 4] 1 shows a ready-to-use hydrated biological suture. [Diagram 5] The steps required to fabricate a pocket-shaped leaflet are shown. (A) A sheet of tissue consisting of ECM (hydrated) secreted by cultured cells is placed on a cutting surface containing an elliptical (8 cm long, 3 cm wide) pattern (solid black line) and allowed to dry. (B) Once dry, the sheet of tissue is cut into the pattern. (C) The tissue is rehydrated with a sterile aqueous solution. (D-E) Once rehydrated, the piece of sheet of tissue can be separated from the cutting support and folded back on itself along the dotted black line to form the pocket-shaped leaflet. [Figure 6] FIG. 4 shows pocket valve leaflets closed with overlock stitches using biological sutures. EXAMPLES
[0050] Example 1: Method for manufacturing a completely biological valve leaflet implant and its characteristics This example describes an approach to fabricating a fully biological leaflet implant. In this example, the resulting leaflet is composed of non-living (devitalized) tissue and is fabricated in a sterile condition, thereby eliminating the use of terminal sterilization or fixation steps. All assembly steps are performed in a sterile environment using sterile fluids and instruments. This description is not intended to limit the scope of the invention with respect to the method of fabrication of the leaflet, cell type, cell source, cell age, cell line, culture conditions, shape of the sheet or sheet pieces, number of sheets or sheet pieces, suture material, suturing method, or intended use of the leaflet. Those skilled in the art will readily appreciate that various modifications can be made to the method without departing from the scope and spirit of the invention.
[0051] In this example, tissue sheets were obtained by culturing normal human dermal fibroblasts in T-2 25 cm2 flasks. For each flask, cells were seeded at a density of 10,000 cells / cm2 and grown in a culture medium consisting of DMEM-F12, bovine serum (20%) and sodium ascorbate (500 mM). The whole set was placed in an incubator with a 37°C atmosphere composed of 5% CO2 and 95% air. The culture medium was changed three times a week. After about 3 days, L-shaped rods made of 304 stainless steel were produced. After a culture period of 16 weeks, the culture flasks were cut in half lengthwise with a hot wire and the sheets were removed from the flasks using an internal frame (fixation system that also serves to handle the sheets) used in the production of biological threads and pocket-shaped leaflets. Mechanical studies established that the sheets could withstand a puncture force of about 2300 grams of force.
[0052] To produce the biological suture, a sheet of moist tissue was placed on a cutting surface containing a double helix pattern to produce a ribbon 5 mm wide and 2.4 m long (Figure 2). The sheet of tissue was then allowed to dry on the cutting surface for at least 2 hours in a laminar flow hood. Once dry, the ribbon was then manually cut using curved surgical scissors and then rehydrated and separated from the cutting surface. One end of the ribbon was then twisted on itself using a rotary motor at a speed of 5 revolutions per cm over a length of 2 cm to form a thread (Figure 3). This twisted area was gently massaged during twisting and until the ends were completely dry, reducing the thread diameter as much as possible (Figure 4). This dry thin area was then inserted into the eye of a surgical needle and the mount was crimped using a pneumatic crimper (Figure 4). The crimped biothread was then dry wrapped around a silicone tube, placed in an Eppendorf tube, and stored at -80°C until use. For use, the biological sutures were rehydrated with water for at least 10 min (Figure 5).
[0053] To obtain particles containing viable cells, the patient's native pulmonary valve leaflets were surgically removed and then separated using a scalpel blade. The particles were then drawn into a syringe for delivery to the pocket valve leaflets.
[0054] To form the pocket leaflets, a sheet of wet tissue was placed on a cutting surface containing an elliptical pattern (length: 8 cm, width: 3 cm) and dried in a laminar flow hood for at least 2 hours. The dried sheet was then cut into the pattern using curved scissors. Once cut, the tissue was rehydrated with water for at least 30 minutes and particles containing live cells were placed on half of the surface of the sheet piece that would form the pocket leaflets using a syringe. Finally, the sheet piece was folded along the short axis of the ellipse (3 cm) to obtain pocket leaflets with dimensions of 4 cm in height and 3 cm in width. Biological sutures were then used to close the free edges of the pocket leaflets using an "overlock" suture technique (Figure 6). To prevent pulmonary leakage in patients resulting from enlargement of the pulmonary outflow tract during surgical correction of tetralogy of Fallot, the leaflets are finally sutured approximately 1 cm above the pulmonary annulus using biological sutures or tapes similar to those used to close the pocket, or synthetic sutures or tapes.
[0055] List of References 1. Apitz et al., Lancet, 374:1462-1471, 2009 2.Warnes et al., ACC Cardiosource Rev.J., 17:19-23, 2008 3. Singh et al., CongenitHeart Dis, 13:935-943, 2018 4. Scavo et al., ASAIO J., 44:M480-M485, 1998 5.Gundry et al., Pediatr.Card.Surg.Annu.Semin.Thorac.Cardiovasc.Surg,2:77-82,1999 6. Turrentin et al., Ann. Thorac. Surg, 73:871-880, 2002 7. Mather et al., Cardiovasc. Pathol.21:e35~e38, 2012 8. Shrivastava et al., Int. J. Cardiol., 25:27~31, 1989 9.Bhukar et al., J.Card.Surg,32:476-478,2017 10. L'Heureux et al, FASEB J.,12:47-56,1998 11. Peck et al., Cells Tissues Organs, 195:144-158, 2011 12. Peck et al., Mater. Today, 14:218-224, 2011 13. Magnan et al., Acta Biomater, 82:56-67, 2018 14. Magnan et al., Acta Biomater, 105:111-120, 2020 15. Wystrychowski et al., J. Vase. Surg, 60:1353-1 357,2014 16.Wystrychowski et al., J.Vase.Access,12:67-70,2011 17. L'Heureux et al, N. Engl. J. Med., 357:1451-1453, 2007 18. McAllister et al., Lancet, 373:1440-1446, 2009 19. International Publication No. 2013 / 142879 20. International Publication No. 2007 / 123658 21. Pande et al., Ann Card Anaesth, 25:164–170, 2022, doi:10.4103 / aca.aca_22_21. 22. U.S. Patent Application No. 20030229394 23. Magnan et al., Biomaterials, 273:120815, 2021, doi: 10.1016 / j.biomaterials2021.120815 24. Wang et al., J Bioact Compatible Polym, 21:39-54, 2006, doi:10.1177 / 0883911506060201 25. Srivastava et al., Biomaterials, 11:155-161, 1990 26.Magnanら、Acta Biomater、82:56~67、2018、doi:10.1016 / j.actbio 2018.10.006 27.Kaweckiら、Biomaterials Science、2022、doi:10.1039 / d1 bm01933c
Claims
1. 1. A pocket leaflet implant, comprising: A pocket-type leaflet implant comprising a piece of tissue sheet consisting of cells in culture, preferably a human, with extracellular matrix secreted by the cells, and optionally the cells folded upon themselves to form a pocket region, wherein all or a portion of the opposing edges of the folded piece are joined to one another, with the understanding that the cells are not human embryonic stem cells, whether genetically modified or not.
2. 10. The valve leaflet implant of claim 1, wherein all or some of the opposing edges of the folded pieces are joined together by sutures using threads or ribbons derived from biologically modified, synthetic and / or tissue sheets.
3. 3. The valve leaflet implant of claim 1 or 2, wherein the implant comprises a biological sample and / or an active ingredient within the pocket area, it being understood that the biological sample is not a genetically modified or non-genetically modified human embryonic stem cell.
4. The valve leaflet implant of claim 3 , wherein the biological sample is derived from at least one leaflet of a subject's valve.
5. 1. A method comprising: a) culturing a sheet of tissue according to claim 1; b) cutting pieces of said sheet of tissue obtained in step a); c) folding the piece from step b) once upon itself to form a pocket area; d) joining all or a portion of the opposing edges of the folded piece from step c).
6. The method according to claim 5, wherein the joining in step d) is performed by suturing with modified, synthetic and / or tissue sheet derived biological threads or ribbons.
7. 7. The method of claim 5 or 6, wherein the method further comprises a step d') of filling the pocket area with a previously collected biological sample and / or an active ingredient prior to full completion of step d).
8. 8. The method of claim 7, wherein the previously collected biological tissue sample is from at least one valve leaflet of a subject.
Citation Information
Patent Citations
Stents for valve replacement - valves and associated methods and systems for surgery
JP2010502320A
Regenerative heart valves for transcatheter repair
JP2015512288A
Prosthetic cardiac valve formed from pericardium material and methods of making same
US20070233228A1
